Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting
06 déc. 2020 08h00 HE
|
Constellation Pharmaceuticals , Inc.
67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeksCPI-0610 demonstrated activity, both as a monotherapy and as add on to...